secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-050145
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q3 total rev $179.5M (+6% YoY); GAAP net income $5.4M vs loss; guides FY rev lower, gross margin higher
--------------------------------------------------------------------------------

- Total revenues $179.5M, up 6% YoY; EXPAREL $139.9M (volume +9% offset by mix and discounting).
- GAAP net income $5.4M ($0.12/share) vs net loss of $143.5M in Q3 2024, which included $163.2M goodwill impairment.
- Adjusted EBITDA $49.4M vs $54.7M; non-GAAP net income $31.8M ($0.72 diluted) vs $38.2M ($0.79) prior year.
- FY2025 revenue guidance lowered to $725-735M from $730-750M; non-GAAP gross margin raised to 80-82% from 78-80%.
- Repurchased 2.0M shares for $50M; $200M remaining on authorization; exclusive license of AMT-143 (ropivacaine) with $5M upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/0001628280-25-050145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/pcrx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-050145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer